GSK plc





Market Closed - London Stock Exchange 11:35:13 2023-12-08 am EST Intraday chart for GSK plc 5-day change 1st Jan Change
1,434.4 GBX +0.13% -0.11% -0.22%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading MT
THG backer Kelso pushes for demerger to trim "inherent" valuation gap AN
Frasers confident; DS Smith profit down, CEO to leave AN
GSK : Receives a Buy rating from Deutsche Bank ZD
Merck KGaA suffers major blow as MS drug fails in late-stage trials RE
Anything is possible
JPMorgan Raises GSK PT, Maintains Underweight Rating MT
Analyst recommendations: Broadcom, Deere & Co, Rio Tinto, Lululemon, Nike...
Goldman lifts Landsec and British Land AN
GSK : JP Morgan keeps a Sell rating ZD
GSK to Discontinue Manufacturing Integrilin Due to Ingredient Supply Issue MT
GSK : JP Morgan keeps a Sell rating ZD
GSK : Deutsche Bank reaffirms its Buy rating ZD
Hopes of an end to rate hikes lift UK shares, for now...
UK Stocks-Factors to watch on Dec 1 RE
GSK CEO Projects Over GBP1 Billion in RSV Vaccine Sales in First Year MT
GSK CEO says RSV vaccine revenue to top 1 bln pounds in first year RE
Transcript : GSK plc - Special Call CI
Pfizer disappointed in RSV shot's market share, CFO says RE
Novartis Touts R&D Pipeline Progress, Upgraded Midterm Targets as Pure-play Medicines Company MT
GSK : Receives a Buy rating from Deutsche Bank ZD
GSK Says Phase 3 Study of Blenrep With BorDex in Multiple Myeloma Meets Primary Endpoint MT
GSK announces positive results from Blenrep phase 3 blood cancer trial AN
GSK: encouraging results in multiple myeloma CF
Chart GSK plc
More charts
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. Its vaccine portfolio includes more than 20 vaccines that help protect people from a range of diseases and infections throughout their lives. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD), antibiotics, and medicines for skin diseases. The Company owns camlipixant, a selective P2X3 antagonist, which is in Phase III development for the treatment of refractory chronic cough (RCC).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
More Ratings
Mean consensus
Number of Analysts
Last Close Price
Average target price
Spread / Average Target
1st Jan change Capi.
-0.22% 73 295 M $
+63.47% 538 B $
+42.56% 430 B $
-12.58% 372 B $
-7.63% 264 B $
-6.49% 263 B $
-12.81% 232 B $
+1.35% 198 B $
-9.77% 197 B $
-43.83% 163 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock GSK plc - London Stock Exchange
  4. News GSK plc
  5. GSK Says Respiratory Syncytial Virus Vaccine Receives Approval in Japan
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration